Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Granuloma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Granuloma. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-005300-15 Sponsor Protocol Number: 201201 Start Date*: 2012-03-27
    Sponsor Name:University Hospital Hvidovre
    Full Title: Treatment of Granuloma Umbilical in newborn babies - comparison of treatment with Silver Nitrate versus alcohol swaps versus steroid creme group IV.
    Medical condition: Granuloma Umbilical
    Disease:
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001810-18 Sponsor Protocol Number: 1503 Start Date*: 2007-09-06
    Sponsor Name:University Hospital Of North Staffordshire
    Full Title: Treatment of gastrostomy related granuloma using hydrocortisone or tea tree oil: A randomized controlled trial.
    Medical condition: Granulomas related to gastrostomy sites in children
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004385-17 Sponsor Protocol Number: MEA115921 Start Date*: 2013-11-22
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving St...
    Medical condition: Treatment of Eosinophilic Granulomatosis with Polyangiitis in Subjects Receiving Standard of Care Therapy.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004867 10018701 Granulomatous disease LLT
    17.1 100000004864 10014956 Eosinophilic granuloma LLT
    17.1 100000004866 10072580 Granulomatous polyangiitis LLT
    17.1 100000004870 10014957 Eosinophilic granulomatous vasculitis LLT
    17.1 100000004866 10056218 Necrotising granulomatous vasculitis LLT
    17.1 100000004855 10068462 Eosinophilic asthma LLT
    17.1 100000004866 10036023 Polyangiitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003162-25 Sponsor Protocol Number: MEA116841 Start Date*: 2015-02-26
    Sponsor Name:GlaxoSmithKline Research Ltd
    Full Title: Mepolizumab Long-term Access Programme for Subjects who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in...
    Medical condition: Eosinophilic Granulomatosis with Polyangiitis (formerly known as Churg-Strauss Syndrome)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004867 10018701 Granulomatous disease LLT
    21.1 100000004866 10072580 Granulomatous polyangiitis LLT
    21.0 100000004864 10014956 Eosinophilic granuloma LLT
    20.1 100000004870 10014957 Eosinophilic granulomatous vasculitis LLT
    21.1 100000004866 10056218 Necrotising granulomatous vasculitis LLT
    21.1 100000004855 10068462 Eosinophilic asthma LLT
    21.1 100000004866 10036023 Polyangiitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-005244-42 Sponsor Protocol Number: 20159990 Start Date*: 2018-06-04
    Sponsor Name:Leiden University Medical Center
    Full Title: An Open-label, Multi-center, Phase 2 Study of Denosumab in Subjects with Giant Cell Rich Tumors of Bone.
    Medical condition: Aneurysmal bone cysts, giant cell granuloma, other giant cell rich lesions (primary bone, non-malignant)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10018252 Giant cell granuloma peripheral LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004430 Benign osteoblastoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008686 Chondroblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008733 Chondromyxoid fibroma LLT
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10002362 Aneurysmal bone cyst PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014572-22 Sponsor Protocol Number: CDP0902 Start Date*: 2010-07-22
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: The use of topical propranolol in pyogenic granulomas
    Medical condition: pyogenic granulomas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029539 LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003042-16 Sponsor Protocol Number: IIBSP-PTE-2018-35 Start Date*: 2019-02-08
    Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau
    Full Title: Randomized clinical trial to evaluate the efficacy of fibrin membrane graft with eye drops concentrated in autologous growth factors in primary pterygium surgery comparing it with amniotic membrane...
    Medical condition: Pterigyum
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001992-34 Sponsor Protocol Number: EVM-22656 Start Date*: 2020-10-29
    Sponsor Name:GALDERMA Research & Development LLC
    Full Title: Clinical Trial Exit Interview Study in Cutaneous T-cell Lymphoma (CTCL) to Capture Meaningful Treatment Benefit from a Patient’s Perspective
    Medical condition: Cutaneous T Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10028483 Mycosis fungoides LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-006157-24 Sponsor Protocol Number: AP3001 Start Date*: 2007-01-31
    Sponsor Name:TopoTarget A/S
    Full Title: A multicenter open label phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma
    Medical condition: Primary cutaneous lymphomas are non-Hodgkin lymphomas that present to the skin without evidence of extracutaneous disease at the time of diagnosis. It refers to either to cutaneous T-cell lymphoma...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028483 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002491-24 Sponsor Protocol Number: BMS-IM101-563 Start Date*: 2016-05-11
    Sponsor Name:Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor
    Full Title: Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease
    Medical condition: CVID patients confirmed according to ESID/PAGID criteria or related disorders which fulfill the diagnostic criteria for CVID and interstitial lung disease or granuloma diagnosed by chest CT positiv...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    18.1 10021428 - Immune system disorders 10021449 Immunodeficiency common variable PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005280-27 Sponsor Protocol Number: AFF006A Start Date*: 2013-06-11
    Sponsor Name:AFFiRiS AG
    Full Title: A randomized, controlled, parallel group, double-blind, multi-centre, phase IIb study to assess safety and clinical activity of continued AFFITOPE® AD02 vaccinations of patients who participated in...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) SK (Completed) HR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001746-32 Sponsor Protocol Number: EORTC 21012 Start Date*: 2005-08-31
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Phase II clinical trial with Caelyx mono-chemotherapy in patients with advanced Mycosis fungoides stage IIb, IVa and IVb with or without previous chemotherapy
    Medical condition: patients with refractory or relapsed advanced stages of mycosis fungoides (stage IIb, IVa, or Ivb)
    Disease: Version SOC Term Classification Code Term Level
    7.0 10028484 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001656-35 Sponsor Protocol Number: LIFE-02-MF Start Date*: 2019-01-10
    Sponsor Name:Dept.Dermotology , Aarhus University
    Full Title: Metabolic imaging of patients with mycosis fungoides using hyperpolarized 13C-Pyruvate magnetic resonance imaging – A feasibility study
    Medical condition: mycosis fungiodes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028483 Mycosis fungoides PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-003701-24 Sponsor Protocol Number: 21011 Start Date*: 2004-12-10
    Sponsor Name:E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER
    Full Title: A RANDOMISED, OPEN-LABEL PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF BEXAROTENE (TARGRETIN) CAPSULES COMBINED WITH PUVA, COMPARED TO PUVA TREATMENT ALONE IN PATIENTS WITH MYCOSIS FUNGOIDES.
    Medical condition: CUTANEOUS T CELL LYMPHOMA.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-001677-16 Sponsor Protocol Number: RD.03.SPR.104003 Start Date*: 2018-04-05
    Sponsor Name:Galderma S.A.
    Full Title: A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous...
    Medical condition: Cutaneous T Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10028483 Mycosis fungoides LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004891-20 Sponsor Protocol Number: 1754-CLTF Start Date*: 2021-03-09
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Study to determine the aetiology of chlormethine gel induced-skin drug reaction in early stage mycosis fungoides cutaneous T cell lymphoma (MF-CTCL)
    Medical condition: Early stage mycosis fungoides cutaneous T cell lymphoma (MF-CTCL)
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10028483 Mycosis fungoides LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001447-39 Sponsor Protocol Number: AB15003 Start Date*: 2019-10-21
    Sponsor Name:AB SCIENCE
    Full Title: A 24-week with possible extension, prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel group with a randomization 1:1, phase III study to compare efficacy and safety ...
    Medical condition: Smouldering or Indolent Severe Systemic mastocytosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Ongoing) PL (Ongoing) RO (Ongoing) LT (Completed) NL (Temporarily Halted) IT (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2018-000727-13 Sponsor Protocol Number: MRG106-11-201 Start Date*: 2018-12-17
    Sponsor Name:miRagen Therapeutics, Inc.
    Full Title: SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymp...
    Medical condition: Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10028483 Mycosis fungoides LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) DE (Completed) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-001845-34 Sponsor Protocol Number: AMBIHOW Start Date*: 2011-09-15
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: LIPOSOMAL AMPHOTERICIN B (AMBISOME) 10 mg/kg once a week for 10 weeks as maintenance antifungal therapy for Proven/Probable Invasive Fungal Infection in hematologic patients with Acute Myeloid Leuk...
    Medical condition: Proven/Probable Invasive Fungal Infection in hematologic patients with Acute Myeloid Leukaemia and/or in Allogeneic Hematopoietic Stem Cell Transplant recipients.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10061730 Bone marrow transplant PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    14.1 10005329 - Blood and lymphatic system disorders 10028484 Mycoses fungoides HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003680-35 Sponsor Protocol Number: 1652-CLTF Start Date*: 2019-01-31
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb-IV mycosis fungoides/sezary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT)
    Medical condition: Subtypes of Cutaneous T cell ltymphoma (CTCL): Mycosis Fungoides (MF) and Sézary Syndrome (SS)
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028508 Mycosis fungoides/Sezary syndrome LLT
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028483 Mycosis fungoides LLT
    20.0 10005329 - Blood and lymphatic system disorders 10028484 Mycoses fungoides HLT
    20.0 10005329 - Blood and lymphatic system disorders 10025321 Lymphomas non-Hodgkin's T-cell HLGT
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10040785 - Skin and subcutaneous tissue disorders 10042356 Skin and subcutaneous conditions NEC HLT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040790 Skin and subcutaneous tissue disorders NEC HLGT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) AT (Completed) GR (Completed) IT (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:11:22 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA